Evidence map›Paper›PMID 41030440›Full record

ArticleFrontiers in immunology2025

Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.

DeAnna J Friedman-Klabanoff, Travis L Jensen, Kirsten E Lyke, Matthew B Laurens, Joana C Silva, Emily M Stucke, Amed Ouattara, Olukemi O Ifeonu, Theresa Hodges, Kara A Moser and 10 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

DeAnna J Friedman-KlabanoffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Travis L JensenBioinformatics and Data Science, The Emmes Company, Rockville, MD, United States.
Kirsten E LykeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Matthew B LaurensCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Joana C SilvaInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Emily M StuckeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Amed OuattaraCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Olukemi O IfeonuInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Theresa HodgesInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Kara A MoserInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Casey E GelberBioinformatics and Data Science, The Emmes Company, Rockville, MD, United States.
Johannes B GollBioinformatics and Data Science, The Emmes Company, Rockville, MD, United States.
Stephen L HoffmanSanaria, Inc., Rockville, MD, United States.
Jigar J PatelNimble Therapeutics, Inc., Madison, WI, United States.
Richard S PinapatiNimble Therapeutics, Inc., Madison, WI, United States.
John C TanNimble Therapeutics, Inc., Madison, WI, United States.
Gregory A DeyeParasitology and International Programs Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Shannon Takala-HarrisonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Mark A TravassosCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Andrea A BerryCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.

Funding

University of Maryland FIRST ProgramU54CA272205 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI JAMES B KAPER, William Richard LaCourse · 2022 to 2026
$18.1M
Serological markers of natural immunity to Plasmodium falciparum infectionK23AI155838 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FRIEDMAN-KLABANOFF, DEANNA · 2021 to 2025
$949k
Protein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915k
Designing a diversity-covering multiantigen multi-strain vaccineK01HL140285 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI OUATTARA, AMED · 2019 to 2023
$712k
NCI NIH HHS U54 CA272205NHLBI NIH HHS K01 HL140285NIAID NIH HHS K23 AI125720NIAID NIH HHS K23 AI155838
6 · The paper itself

Abstract

Introduction: Extensive Methods: We designed a novel diversity-reflecting peptide microarray containing 638,817 unique peptides representing 22,655 variants of 227 proteins from 23 P Results: While the two CHMI groups had similar intensity of responses to all proteins on the array, 20 proteins on the array had differential breadth of responses and participants infected with 7G8 strain had a higher breadth of responses to 17 of them. Of 543 ABCPred-predicted epitopes, 66 overlapped with MEME-identified epitopes, six of which were highly cross-reactive with >95% of peptide variants serorecognized by at least one CHMI group. Discussion: Overall, we found most antibody responses to be comparable after infection with the NF54 strain or 7G8 strain, but we saw notable differences for ~10% of proteins on the array. While many MEME-identified epitopes from highly cross-reactive proteins were asparagine rich, an epitope from PF3D7_1033200 (ETRAMP10.2) was not. Highly cross-reactive responses to ETRAMP10.2 could be further characterized and ETRAMP10.2 could be considered for inclusion in a next generation vaccine.

Indexed as

Antibodies, ProtozoanAntibody FormationAntigens, ProtozoanMalaria, FalciparumPeptidesPlasmodium falciparumProtozoan ProteinsAdultCross ReactionsEpitopesFemaleHumansMaleProtein Array AnalysisYoung AdultAntibodies, ProtozoanAntigens, ProtozoanEpitopesPeptidesProtozoan Proteinscontrolled human malaria infectionepitopehumoral immunity to malariamalariapeptide microarraysPlasmodium falciparum

Identifiers

PMID41030440
PMCPMC12477171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.